AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Published: May 14, 2021 | Tags: AzurRx BioPharma, P-II, MS1819, PERT, Cystic Fibrosis, Severe, Exocrine Pancreatic Insufficiency Goldfinch Bio Initiates P-I Clinical Trial of GFB-024 for the Treatment of Severe Insulin Resistant Diabetic Nephropathy Published: […]Read More
Shots: Nanobiotix to receive a $20M up front and is eligible to receive ~$220 M as contingent payments and milestones along with royalties on net sales of NBTXR3 in the licensed countries LianBio to get exclusive rights to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand LianBio supports the expansion of […]Read More
Takeda’s Alunbrig (brigatinib) Receives MHLW’s Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC Published: Jan 22, 2020 | Tags: Takeda, Alunbrig, (brigatinib), Receives, MHLW, Approval,1L and 2L, Treatment, ALK+ Advanced or Recurrent NSCLC MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the […]Read More
Shots: The complete dose-finding part of P-Ib/II study assessed the safety, feasibility, and RP2D of NBTXR3 (intratumoral inj.) in 20 patients with LA (T3 to T4) or unresectable rectal cancer The study showed ORR after CCRT in >70% patients, 90% patients underwent total mesorectal excision (surgery); 17.6% achieved pCR; 50% receiving surgery had good tumor […]Read More
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased […]Read More
Shots: Nanobiotix launches a new subsidiary, Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability, toxicity, and efficacy in the healthcare system in France & the US Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
